News headlines about Ra Pharmaceuticals (NASDAQ:RARX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.4056927366894 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Ra Pharmaceuticals (RARX) opened at $14.23 on Monday. Ra Pharmaceuticals has a 52 week low of $11.20 and a 52 week high of $27.84.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). research analysts predict that Ra Pharmaceuticals will post -2.46 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/04/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-ra-pharmaceuticals-rarx-share-price.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
What are top analysts saying about Ra Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ra Pharmaceuticals Inc and related companies.